Premium
NEGRAM (1‐ethyI‐7‐methyl‐1, 8‐naphthyridine‐4‐one‐3‐carboxylic acid): A NEW ANTIBACTERIAL AGENT FOR THE TREATMENT OF URINARY INFECTION Report of a Trial in General Practice
Author(s) -
Thompson R. E. M.,
Rae J.
Publication year - 1964
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1964.tb09478.x
Subject(s) - nalidixic acid , urinary system , urine , in vivo , antibiotics , medicine , drug , in vitro , general practice , pharmacology , microbiology and biotechnology , chemistry , family medicine , biology , biochemistry , ampicillin
SUMMARY A new compound, Negram (nalidixic acid), was used by thirty‐three general practitioners who treated 114 patients suffering from urinary infections. The dose was 4 g. per day for either five, seven, or ten days. The results of treatment were controlled bacteriologically by the examination of the urine. Negram was effective in vivo and in vitro against Gram‐negative organisms, but had no effect upon Gram‐positive infections. Patients tolerated the drug well and only minor side effects are reported. We would like to thank the general practitioners who took part in the trial. Thanks are also due to Dr A. L. Miller, Chemical Pathologist, Courtauld Institute of Biochemistry, who investigated the identity of the reducing substance; to Mr B. G. Beesley who carried out the technical work and to Mr P. J. ODonnell who organised the trial.